J Korean Soc Pediatr Endocrinol Search


Ann Pediatr Endocrinol Metab > Volume 16(3); 2011 > Article
DOI: https://doi.org/10.6065/jkspe.2011.16.3.157   
A Single-Arm, Phase III Study to Assess Efficacy and Safety after 6-Month-Treatment of Eutropin(TM) Inj. (Recombinant Human Growth Hormone) in Prepubertal Children with Short Stature due to Small for Gestational Age.
Kee Hyoung Lee, Byung Churl Lee, Cheol Woo Ko, Dong Kyu Jin, Sei Won Yang, Han Wook Yoo, Woo Yeong Chung, Duk Hee Kim, Byung Kyu Suh
1Department of Pediatrics, Korea University Hospital, Seoul, Korea.
2Department of Pediatrics, The Catholic University St. Mary's Hospital, Seoul, Korea.
3Department of Pediatrics, Kyungpook National University Hospital, Daegu, Korea.
4Department of Pediatrics, Samsung Medical Center, Seoul, Korea.
5Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.
6Department of Pediatrics, Asan Medical Center, Seoul, Korea.
7Department of Pediatrics, Inje University Busan Paik Hospital, Busan, Korea.
8Department of Pediatrics, Severance Hospital, Seoul, Korea.
9Department of Pediatrics, The Catholic University Seoul St. Mary's Hospital, Seoul, Korea. suhbk@catholic.ac.kr
Recombinant human growth hormone is an effective therapy for short-statured children born small for their gestational age (SGA). This single-arm, multicenter, phase III clinical study of such children was designed to assess the efficacy and safety of treating them with recombinant human-growth-hormone (Eutropin(TM) Inj.) for 6 months. METHODS: Between 2005 and 2007, 30 treatment naive, prepubertal, short-statured SGA-born children were recruited as participants. Eutropin(TM) Inj. was administered for 6 months with a subcutaneous dose of 0.48 mg/kg/wk. The primary endpoint was the change in height velocity from the baseline to month 6. Various parameters were checked to obtain secondary outcome measures and to meet safety criteria.
Height velocity significantly increased from 5.36 +/- 1.59 cm/yr at baseline to 10.66 +/- 2.03 cm/yr at month 6 (P < 0.0001). Secondary outcome measures (height velocity at month 3, height SDS for chronological age (CA), weight SDS for CA, bone maturation, and IGF-I and IGFBP-3 levels) were also significantly increased. Eutropin(TM) Inj. was well tolerated and safe over 6 months of treatment.
The clinical efficacy and safety of Eutropin(TM) Inj. was demonstrated for the 6 month treatment of prepubertal children with short stature due to SGA. Further long-term study is needed.
Keywords: Human growth hormone;Small for gestational age;Short stature
Share :
Facebook Twitter Linked In Google+
METRICS Graph View
  • 5 Crossref
  • 5,157 View
  • 67 Download
Related articles in APEM


Browse all articles >

Editorial Office
501-107, 30 Seocho-daero 74-gil, Seocho-gu, Seoul 06622, Republic of Korea
Tel: +82-2-3471-4268    Fax: +82-2-3471-4269    E-mail: editor@e-apem.org                

Copyright © 2024 by Korean Society of Pediatric Endocrinology.

Developed in M2PI

Close layer
prev next